echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Diagnostic Test > Roche's oncology business continued to be impacted by biosimilars in the first quarter, and total sales fell by 19...

    Roche's oncology business continued to be impacted by biosimilars in the first quarter, and total sales fell by 19...

    • Last Update: 2021-05-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Compile Ke Ke

    Roche President Bill Anderson (Bill Anderson) introduced in a conference call on Wednesday (April 21) that in the first quarter of 2021, the company’s biosimilar business sales were 1.
    6 billion Swiss francs (approximately 17.
    4).
    100 million U.
    S.
    dollars), at a constant exchange rate, this decline in revenue led to a 19% decline in total tumor sales.

    Once Roche’s best-selling "troika" Avastin, Herceptin and Rituxan are currently ranked third and sixth on the company’s best-selling drug list.
    And seventh.

    Avastin's sales during the quarter fell sharply by 42% to 863 million Swiss francs.
    And Herceptin fell 37% year-on-year to 755 million Swiss francs.
    Rituximab sales fell by nearly half to 705 million Swiss francs.

    On the other hand, Roche also successfully launched the multiple sclerosis (MS) drug Ocrevus and declared that the drug is the sales champion.
    The drug's revenue in the first quarter was 1.
    23 billion Swiss francs, an increase of 10% over the same period last year.

    At the same time, investors have high hopes for Roche's PD-L1 inhibitor Tecentriq, but Anderson tried to adjust the outside world's expectations for important new uses of Tecentriq in a conference call on Wednesday.
    Sales of the drug in the first quarter were 775 million Swiss francs, only lower than the drug Actemra, which is used to treat patients with severe COVID-19, which had sales of 779 million Swiss francs.

    Roche recently released the results of a first-in-class positive study showing that Tecentriq can prevent postoperative recurrence or death in patients with early-stage non-small cell lung cancer.
    Despite these advances, analysts have expressed caution about possible use, pointing out that doctors would rather see if the drug can extend lifespan before changing their practices.

    Overall, Roche Pharmaceuticals’ sales reached 10.
    6 billion Swiss francs, a 14% decrease year-on-year.
    The company called the extent of the erosion of the biosimilar drug market "in anticipation" and maintained its group-wide forecast.
    It is expected that the company's sales will grow at a constant exchange rate in 2021, from low to mid-single digits.

    Next week, the US FDA Advisory Committee will discuss two indications of Tecentriq.
    One is for some newly diagnosed bladder cancer patients who are not eligible for cisplatin chemotherapy, and the other is a chemotherapy drug with Bristol-Myers Squibb.
    Abraxane combined treatment of PD-L1-positive triple-negative breast cancer.
    The company remains confident in maintaining these indications, but Anderson pointed out that the two indications market is a secondary component of the drug.

    In addition, despite the failure of these COVID assets, Roche continued to make progress during the COVID-19 pandemic in the first quarter of this year, especially in the diagnostics department.
    According to Roche, its rapid SARS-CoV-2 antigen nasal test can quickly identify people at the highest risk of infection, and has obtained special approvals for CE marking and self-testing in several European countries.
    In addition, the cobas SARS-CoV-2 Variant Set 1 test, which the company is studying and using, has been launched this quarter to help the world monitor the mutation of the new coronavirus.

    Also in the first quarter, Roche acquired GenMark Diagnostics for US$1.
    8 billion to promote the development of the diagnostic business.
    The company is one of the first companies to obtain emergency use authorization from the US FDA.
    The key product is the ePlex SARS-CoV-2 test, which will supplement Roche’s own COVID-19 test, which has its own IL-6 test including Elecsys , Which measures the level of IL-6 (Interleukin-6); and Elecsys's anti-SARS-CoV-2 antibody test.

    In terms of therapeutics, Roche emphasized the partnership with Regeneron.
    The company said that the casirivimab/imdevimab antibody combination is currently benefiting patients in more and more countries including the United States, Germany, Italy, France and Switzerland, and the antibody combination continues to show positive clinical results.
    In the Phase 3 clinical study to prevent COVID-19, the casirivimab/imdevimab cocktail reduced symptoms of infection by 81% and reduced hospitalizations or deaths by 70%.

    Reference source:

    Reference source:

    1.
    Roche Quietly Pulls Two Phase II COVID-19 Studies in Q1

    1.
    Roche Quietly Pulls Two Phase II COVID-19 Studies in Q1

    2.
    Roche feels more biosimilar pain as exec pulls back expectations for Tecentriq in early lung cancer

    2.
    Roche feels more biosimilar pain as exec pulls back expectations for Tecentriq in early lung cancer
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.